<div id="readability-page-1">11:58 AM EDT, 05/15/2026 (MT Newswires) -- Danaher ( DHR ) could see about 6% revenue growth in 2027, driven by a rebound in bioprocess demand trends and improving end markets, RBC Capital Markets said.RBC's channel checks indicate robust demand trends for bioprocess consumables and expanding equipment funnels, according to the note. This positions Danaher ( DHR ) to benefit from the sector recovery as bioprocessing represents more than 25% of the company's revenue, the investment firm said in a Thursday note.Danaher ( DHR ) is also working to close menu gaps in its Beckman Coulter business and sees continued improvement in its molecular diagnostics segment amid a recovering underlying diagnostics market. The company could see further growth upside from its Masimo (MASI) acquisition, which is expected to close in the second half of 2026, RBC added.RBC Capital Markets resumed coverage on Danaher ( DHR ), with an outperform rating and a $200 price target.Shares of Danaher ( DHR ) were down 1.1% in Friday afternoon trading.Price: 162.75, Change: -1.79, Percent Change: -1.09 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

丹纳赫

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

标普健康医疗设备 ETF - SPDR

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

美国医药设备 ETF - iShares

标普生物技术 3 倍做多 - Direxion

RBC 资本市场预测，丹纳赫（Danaher，股票代码：DHR）在 2027 年可能实现 6% 的收入增长，这得益于生物处理需求的反弹和市场的改善。该公司指出，生物处理耗材和设备的需求强劲。丹纳赫还在解决其贝克曼库尔特（Beckman Coulter）业务中的不足，并预计其收购马西莫（Masimo）将带来增长。尽管股价下跌 1.1% 至 162.75 美元，RBC 仍恢复了对该公司的覆盖，给予 “跑赢大盘” 的评级，并设定 200 美元的目标价

Danaher Seen on Path to Growth Reacceleration on Bioprocess Recovery, RBC Says

fidelity

加拿大皇家银行

麦斯莫医疗

RBC 表示，丹纳赫在生物工艺恢复的推动下被视为重新加速增长